重药控股股份有限公司2025年半年度报告摘要

Core Points - The company has undergone a change in its actual controller, with a 2% equity transfer from Chongqing Chemical Medicine Holdings to China General Technology Group [5][6][7][8] - The company has approved a share repurchase plan during the board meeting held on July 10, 2025, which was subsequently ratified by the shareholders [8][10] - The company has also reported the release of pledged shares by its controlling shareholder, involving 109,867,400 shares [8][9] Company Overview - The company is identified as Chongqing Pharmaceutical Holdings, with the stock code 000950 [1] - The board of directors has confirmed that all members attended the meeting to review the report [2] - The company has not proposed any cash dividends or stock bonuses for the reporting period [3] Financial and Operational Highlights - The company has not experienced any changes in its controlling shareholder during the reporting period [5] - The company has completed the necessary registration procedures for the equity transfer related to the change in actual controller [7] - The board has approved the 2025 semi-annual report and its summary [24][25]